Songül Akcan
Songül Akcan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Aysegul Atmaca
Department of Endocrinology and Metabolism, Ondokuz Mayıs University Faculty of Medicine, Samsun, Türkiye
1 shared publication - Birşen Bilgici
ONDOKUZ MAYIS ÜNİVERSİTESİ, TIP FAKÜLTESİ, TEMEL TIP BİLİMLERİ BÖLÜMÜ, TIBBİ BİYOKİMYA ANABİLİM DALI
1 shared publication - Burhan Savas
Konya Şehir Hastanesi
1 shared publication - Hakan Bozcuk
Dept. of Medical Oncology, Medical Park Hospital, Antalya, Turkey
1 shared publication - Köksal Şerefli
Kırşehir Eğitim ve Araştırma Hastanesi Tıbbi Biyokimya
1 shared publication - Leman Tomak
Ondokuz Mayis University
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 390-399
Chemerin and Sfrp5 levels in subclinical hypothyroidism
Purpose:. This study aimed to investigate the impact of subclinical hypothyroidism on chemerin and Sfrp5 levels. Material and Methods: Forty-six individuals with subclinical hypothyroidism were enrolled in the patient group, and 49 healthy individuals were included as controls. Serum levels of chemerin and Sfrp5 were measured using the ELISA method. LDL cholesterol, total cholesterol, triglycerides, HDL cholesterol, insulin, and glucose levels were simultaneously measured in blood samples and obtained from patients' medical records. Results: In the patient group, a statistically significant positive correlation was found between chemerin and Sfrp5 levels in the Spearman correlation analysis (r = 0.704). When both the patient and control groups were evaluated together, a significant positive correlation was observed between chemerin and Sfrp5 levels (r = 0.814). Additionally, negative correlations were found between Sfrp5 and LDL cholesterol, total cholesterol, triglycerides, body mass index, diastolic blood pressure, and systolic blood pressure (r = -0.320, r = -0.341, r = -0.278, r = -0.383, r = -0.230, and r = -0.206, respectively). Conclusion: In subclinical hypothyroidism, chemerin, an inflammatory marker, tended to be elevated, while Sfrp5, an anti-inflammatory marker, tended to be reduced; however, these changes were not statistically significant. Further studies with larger sample sizes are needed to clarify the role of adipokines and inflammation in the development of subclinical hypothyroidism and to assess whether these parameters could serve as potential biomarkers.
- 30 June 2025
- Published by Cukurova Medical Journal in Cukurova Medical Journal
- Vol. 50 (2) , 390-399
Open AccessChemerin and Sfrp5 levels in subclinical hypothyroidism
Purpose:. This study aimed to investigate the impact of subclinical hypothyroidism on chemerin and Sfrp5 levels. Material and Methods: Forty-six individuals with subclinical hypothyroidism were enrolled in the patient group, and 49 healthy individuals were included as controls. Serum levels of chemerin and Sfrp5 were measured using the ELISA method. LDL cholesterol, total cholesterol, triglycerides, HDL cholesterol, insulin, and glucose levels were simultaneously measured in blood samples and obtained from patients' medical records. Results: In the patient group, a statistically significant positive correlation was found between chemerin and Sfrp5 levels in the Spearman correlation analysis (r = 0.704). When both the patient and control groups were evaluated together, a significant positive correlation was observed between chemerin and Sfrp5 levels (r = 0.814). Additionally, negative correlations were found between Sfrp5 and LDL cholesterol, total cholesterol, triglycerides, body mass index, diastolic blood pressure, and systolic blood pressure (r = -0.320, r = -0.341, r = -0.278, r = -0.383, r = -0.230, and r = -0.206, respectively). Conclusion: In subclinical hypothyroidism, chemerin, an inflammatory marker, tended to be elevated, while Sfrp5, an anti-inflammatory marker, tended to be reduced; however, these changes were not statistically significant. Further studies with larger sample sizes are needed to clarify the role of adipokines and inflammation in the development of subclinical hypothyroidism and to assess whether these parameters could serve as potential biomarkers.
- 12 November 2009
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (6) , 803-809
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR–RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.
- 12 November 2009
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 136 (6) , 803-809
The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan-based regimens
Previous studies have suggested that DNA repair enzyme polymorphisms may bear prognostic value in metastatic colorectal carcinoma (MCRC). We prospectively treated 43 MCRC patients with irinotecan-based regimens (XELIRI or IFL). Allelic variants of the XRCC1 gene at codon 399 and XPD gene at codon 751 were analyzed in lymphocyte DNA by PCR–RFLP. Clinical outcome variables: overall survival (OAS), progression-free survival (PFS) and the occurrence of grade 3 or 4 hematological and gastrointestinal (GIS) toxicities were evaluated. In the univariate analysis for OAS (n = 43) only XPD and XRCC1 polymorphisms were significant (P = 0.05 and P = 0.04, respectively). After adjustment for performance status (ECOG = 0, 1 vs. 2) and disease extent (single vs. multiple metastatic site), XRCC1 genotype and performance status retained significance (HR = 2.85, P = 0.04, and HR = 3.19, P = 0.02, respectively). Gln/Gln genotype was associated with the greatest risk of death. Type of presentation (metastatic vs. local disease at first presentation) was the only significant predictor of PFS in the univariate analysis (n = 40, P = 0.003). After adjustment for performance status and disease extent, type of presentation retained its significance (HR = 4.35, P = 0.003). None of the toxicities was associated with these genotypes. XRCC1 genotype independently predicted overall survival in metastatic colorectal carcinoma patients treated with irinotecan-based chemotherapy.